|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
We demonstrated that the increase of sICAM-1, sVCAM-1 and PAI-1, together with decrease of omentin-1 led to a proinflammatory imbalance pointing to the presence of subclinical atherosclerosis, and improving CVD risk stratification in non-smoking patients at early stage MetS beyond traditional scores.
|
31349950 |
2019 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Plasminogen activator inhibitor ( PAI -1) is associated with excessive fibrin accumulation, thrombus formation, and atherosclerosis.
|
30371230 |
2018 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
AlteredExpression |
BEFREE |
The aim of this cross-sectional study was to evaluate the differences in plasma levels of plasminogen activator inhibitor-1 (PAI-1) and of von Willebrand factor (vWF) as endothelial hemostatic markers and carotid intima-media thickness (C-IMT) as a morphologic marker for atherosclerotic vascular disease among dyslipidemic individuals with apoB levels higher, estimated or lower based on regression equation of apoB vs non-HDL-C.
|
28502501 |
2018 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
The levels of CLOCK, leukemia inhibitory factor (LIF), intercellular adhesion molecule 1 (ICAM-1), perilipin 2 (ADFP), nuclear factor kappa B (NF-κB), and plasminogen activator inhibitor-1 (PAI-1), as well as the number of atherosclerotic plaques were elevated in the AS mouse model, as compared with the control group.
|
30124738 |
2018 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
AlteredExpression |
BEFREE |
In this study we explored the microRNAs responsible for the regulation of PAI-1 during LPS-stimulated inflammation in human aortic endothelial cells and subsequently studied the effect of a newly synthesized mitochondria-targeted esculetin (Mito-Esc) that was shown for its anti-atherosclerotic potential, in modulating PAI-1 levels and its targeted miRs during angiotensin-II-induced atherosclerosis in ApoE<sup>-/-</sup> mice.
|
28213977 |
2018 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
GeneticVariation |
BEFREE |
Therefore, we performed this study to better assess the relationship between PAI-1 genetic variations and atherosclerosis.
|
29908999 |
2018 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Furthermore, PCB126 exposure in MCD-fed mice led to increased plasma inflammatory markers such as Icam-1, plasminogen activator inhibitor-1 and proatherogenic trimethylamine-N-oxide, suggesting inflammation of the peripheral vasculature that is characteristic of atherosclerosis.
|
28973532 |
2017 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Interleukin-6 and plasminogen activator inhibitor-1 did not provide incremental value to fibrinogen when examining the associations with degree of atherosclerosis.
|
27755007 |
2017 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Finally, we explored the causal effect of PAI-1 on cardiovascular risk factors including metabolic and subclinical atherosclerosis measures.
|
28550093 |
2017 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) has been regarded as a risk factor for thrombosis and atherosclerosis.
|
29253845 |
2017 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
GeneticVariation |
BEFREE |
Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
|
28692480 |
2017 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
GeneticVariation |
BEFREE |
In this patient, without traditional risk factors for atherosclerosis, eight mutations and polymorphisms in six different genes were identified: polymorphism of factor V Leiden (1691 GA), factor II prothrombin (20210 GA), methylenetetrahydrofolate reductase (MTHFR, 677 CT and 1298 AC), plasminogen activator inhibitor 1 (PAI-1) polymorphism 4G/5G and glycoprotein VI (GP6, 13254 TC, Ser219Pro).
|
28382527 |
2017 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
PAI-1 has been linked to fibrin deposition that evolves into organ fibrosis and atherosclerosis.
|
28785222 |
2017 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
AlteredExpression |
BEFREE |
Plasma PAI-1 levels and 4G/4G genotype frequency were significantly higher in the severe atheromatosis group compared to the other groups (p<0.001).
|
22011808 |
2011 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
GeneticVariation |
BEFREE |
In this study, we aimed to investigate the effect of tPA (tissue plasminogen activator) and PAI-1 (plasminogen activator inhibitor) antigen concentrations and 4G/5G polymorphism of the PAI-1 gene on the development of atherosclerosis in SLE patients.
|
21719525 |
2011 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
AlteredExpression |
BEFREE |
We tested the hypothesis that leptin induces PAI-1 and inhibits tPA expression using human coronary artery endothelial cells (HCAEC) in culture as these cells play an important role in atherosclerosis.
|
20051227 |
2010 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
PAI-1 is paracrine secretion of pro- and antiinflammatory cytokines, thereby playing a possible role in the adiposity-related inflammation and atherosclerosis.
|
19033264 |
2009 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
The results indicate that ghrelin inhibits both basal and TNF-alpha-induced PAI-1 production via NF-kappaB pathway in HepG2 cells, and suggest that the peptide plays a therapeutic role in atherosclerosis, especially in obese patients with insulin resistance, in whom ghrelin levels were reduced.
|
18700166 |
2008 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Negative correlations between antioxidative defense parameters and BMI, abdominal obesity, insulin secretion, systolic blood pressure and atherogenic lipid factors, as well as correlations between PAI-1 and insulin resistance and basal glycemia in the metabolic syndrome group contribute to accelerated atherosclerosis.
|
17848118 |
2007 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
The effect of PAI-1 upon angiogenesis is also involved in atherosclerosis, in which high levels of PAI-1 expression are observed.
|
17509745 |
2007 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
AlteredExpression |
LHGDN |
Elevated plasma PAI-1 activity was independently associated with coronary microvascular dysfunction, which suggests that plasma PAI-1 activity is an important clue linking hypofibrinolysis to the development of atherosclerosis.
|
17322633 |
2007 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1) is a major physiologic regulator of the fibrinolytic system and has recently gained recognition as a modulator of inflammation and atherosclerosis.
|
16968709 |
2006 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
AlteredExpression |
BEFREE |
In conclusion, obesity and TNF-alpha up-regulation of PAI-1 expression in human hepatocytes may contribute to the impairment of the fibrinolytic system, leading to the development of atherosclerosis and liver fibrosis in insulin-resistant individuals.
|
17046548 |
2006 |
|
SERPINE1
|
Atherosclerosis
|
0.400 |
Biomarker |
LHGDN |
Studies with transgenic mice have revealed a functional role for PAI-1 in wound healing, atherosclerosis, metabolic disturbances such as obesity and insulin resistance, tumor angiogenesis, chronic stress, bone remodeling, asthma, rheumatoid arthritis, fibrosis, glomerulonephritis and sepsis.
|
15634264 |
2005 |